New drug AVM0703 tested for Life-Threatening lung failure
NCT ID NCT04366115
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a single dose of a new drug called AVM0703 in 16 adults with severe breathing failure (ARDS) caused by COVID-19 or the flu. The main goal is to check if the drug is safe and how the body processes it. Participants are randomly assigned to receive the drug or a placebo, and neither they nor their doctors will know which they got.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stem cell infusion may help severely ill COVID-19 patients breathe
- Could a different way of pedaling rebuild muscles after severe COVID-19?
- Can a lab-made flu vaccine outperform the traditional egg-based shot?
- Ancient herbs take on long COVID: a trial tests whether chinese medicine can soothe persistent fatigue
- Bedside flu shot for heart patients: a simple strategy to save lives?
- Can a 15-Minute chat at a testing site boost COVID-19 vaccination?